Compare Eli Lilly And Co (LLY) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Oatly Group AB - ADR — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Oatly Group AB - ADR trades at $10.59 (market cap $330.93M). The key difference: Eli Lilly And Co is far larger — about 3142.7× Oatly Group AB - ADR's market cap, and Eli Lilly And Co pays a 0.59% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Oatly Group AB - ADR for 18 Days on average.
| LLY | OTLY | |
|---|---|---|
Market Cap | $1.04T | $330.93M |
Volume | 3,064,878 | 68,708 |
Sector | Health | Consumer Staples |
52-Week High | $1.28K | $15.91 |
52-Week Low | $799.57 | $8.03 |
Typical Hold Time | 93 Days | 18 Days |
Enterprise Value | $1.09T | $835.34M |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
OTLY trades at $10.38, up 0.1% on the day, with a bearish technical signal but improving fundamentals. Revenue grew to $862.46M in 2025, and net losses narrowed to -$152.77M, showing progress toward profitability. The stock is supported by a consensus price target of $12.28 and positive news around Q2 2026 results, including a raised revenue outlook.
The outlook is cautiously optimistic as cost controls and sales growth may lead to positive EBITDA, but high debt and persistent cash burn pose risks. Analyst sentiment is mixed with 44% buy ratings, reflecting belief in the turnaround story amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
